Navigation Links
QLT announces interim results of radical study evaluating Visudyne combination therapy
Date:12/16/2008

n, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. For more information, visit our website at www.qltinc.com.

    Atrigel is a registered trademark of QLT USA, Inc.
    Lucentis is a registered trademark of Genentech, Inc.
    Visudyne is a registered trademark of Novartis AG.
    Eligard is a registered trademark of Sanofi-Synthelabo Inc.
    QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on the Toronto Stock Exchange under the trading symbol "QLT."

Forward-Looking Statements

Certain statements in this press release constitute "forward looking statements" of QLT within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward looking information" within the meaning of applicable Canadian securities laws. Forward looking statements include, but are not limited to: our expectations for timing to receive and release data from the RADICAL study; any future expectations about the reduced-fluence Visudyne-Lucentis combination therapy; and statements which contain language such as: "assuming," "prospects," "future," "projects," "believes," "expects" and "outlook." Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the Company's future operating results are uncertain and likely to fluctuate; uncertainties re
'/>"/>

SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Pets Best Announces New Underwriter for Pet Insurance Policies
2. Lilly Announces Dividend Increase
3. Anthem Blue Cross and Blue Shield and Summerlin Life and Health Insurance Company Enter Into Endorsement Agreement as Summerlin Announces Exit From the Commercial PPO Business in Nevada
4. Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
5. Musculoskeletal Transplant Foundation Announces Major Development Milestone in Stem Cell Allograft Product
6. DaVita Inc. Announces Receipt of DOJ Subpoena in Connection with Previously Reported Investigation
7. Genomic Health Announces Study Establishing the Utility of Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated with Aromatase Inhibitors
8. Alfacell Announces Management Update
9. Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer
10. Par Pharmaceutical Announces the Resignation of Its Chief Financial Officer
11. Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... WI (PRWEB) March 02, 2015 ... consultancy focused on quality, regulatory and technical consulting, ... as Chief Operating Officer. , Before joining ... experience leading R&D teams in all aspects of ... leadership positions at Covidien (Medtronic), Regulatory Compliance Associates ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 A true renaissance ... leader of the 1960s cult rock band Khazad Doom, has ... his determination to persevere despite all odds. His motto throughout ... matter what situation or goal was before him. And that ... is now being passed on to a new generation. , ...
(Date:3/2/2015)... 2015 In light of the FDA's ... Xarelto (rivaroxaban) tablets, Ford & Associates Nationwide Legal ... for future users, but may come too late for ... the drug. The FDA has now included the term ... on Xarelto's label. The term “cytolytic hepatitis” has also ...
(Date:3/2/2015)... What are the best practices for writing ... are interviews scheduled, how can physicians best prepare, and ... practicing physicians who are looking for new opportunities can ... the PracticeLink Physician Career Advancement Workshop and Job Fair ... from 5:30 to 8:30 p.m. at the Marriott-Texas Medical ...
(Date:3/2/2015)... Bangladesh (PRWEB) March 02, 2015 The ... of fire safety expert Mark Chubb to serve as ... fire safety operations and training in Bangladesh and guide ... source. , “Mark will ensure that the Alliance ... fire safety programs for Bangladesh garment workers,” said Alliance ...
Breaking Medicine News(10 mins):Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2
... front of TV, computer linked to less bonding with peers, ... Too much time in front of computers or televisions increases ... parents and peers, a new study suggests. , The researchers ... who provided details about how they spent their free time ...
... resulting aspirin therapy, may not be needed for healthier patients ... study raises questions about the value of both the ankle-brachial ... blood vessel problems in the legs, and the common practice ... ankle-brachial index (ABI) measures blood pressure in the arm and ...
... ... ... ... ...
... , ... ... , , ... ...
... ... ... ... ...
... , ... , ... , , , , ... ...
Cached Medicine News:Health News:Screen Time May Take a Toll on Kids' Relationships 2Health News:Study Questions Value of Test for Peripheral Artery Disease 2Health News:Study Questions Value of Test for Peripheral Artery Disease 3Health News:Sodexo Names Patricia Bellinger to North America Advisory Board 2Health News:Sodexo Names Patricia Bellinger to North America Advisory Board 3Health News:Sodexo Names Patricia Bellinger to North America Advisory Board 4Health News:IDEXX Laboratories Elects Joseph Vumbacco as Director 2Health News:IDEXX Laboratories Elects Joseph Vumbacco as Director 3Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 2Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 3Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 4Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 5Health News:AMA Honors Maine Governor John Baldacci With Top Government Service Award 2Health News:AMA Honors Maine Governor John Baldacci With Top Government Service Award 3
(Date:3/1/2015)... -- LifeScienceIndustryResearch.com announces Global Angiographic X-ray ... pages along with 8 company profiles added to ... 2015 Market Research Report on Global Angiographic X-ray ... report on Global Angiographic X-ray System market.  For ... basic information including definition, classification, application, industry chain ...
(Date:3/1/2015)... 1, 2015 /CNW Telbec/ -   Ergoresearch Ltd (TSXV: ... and known under the « Équilibre, orthèses et ... quarter Ended on December 31, 2014. All dollar amounts ... Revenues for the second quarter of fiscal ... $ 4 095 112 decreasing by 8,8 % compared to revenues of ...
(Date:3/1/2015)... March 1, 2015  An innovative interventional radiology ... sufferers sustained relief of their headaches, according to ... Interventional Radiology ,s Annual Scientific Meeting . ... University New York Empire State College in Saratoga ... ganglion (SPG) blocks to give patients enough ongoing ...
Breaking Medicine Technology:Global Angiographic X-ray System Industry Research Report 2Global Angiographic X-ray System Industry Research Report 3Global Angiographic X-ray System Industry Research Report 4Global Angiographic X-ray System Industry Research Report 5Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 3Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 4Image-guided treatment shown to break the migraine cycle 2Image-guided treatment shown to break the migraine cycle 3Image-guided treatment shown to break the migraine cycle 4
...  Boston Scientific Corporation (NYSE: BSX ) ... Chromium Coronary Stent System demonstrated non-inferior results in ... at one year compared to the PROMUS Element™ ... First Human Use Trial.  The trial reported one-year ...
... is pleased to announce the acquisition of Assured Packaging, ... custom manufacturer of aerosols for the health and beauty ... Assured Packaging acquisition and the purchase of K-G Spray-Pak ... most diversified custom aerosol filler in Canada. ...
Cached Medicine Technology:One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 2One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 3One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 4One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 5One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 6PLZ Aeroscience Acquires Assured Packaging 2
... Liquichek Qualitative Urine Toxicology Control is ... qualitative rapid urine drug screen panels, including ... (DOA) test kits like Bio-Rad TOX/See, Biosite ... includes qualitative results (+/) for popular kits ...
... Stain is an aqueous new ... in manual methods of reticulocyte ... a one year shelf life ... can be used in conjunction ...
... Liquichek ToRCH Plus IgM ... potential problems in your ToRCH ... affect your test results. Liquichek ... the perfect complement to Liquichek ...
... Liquichek ToRCH Plus Control is ... to monitor the performance of ... instruments and assays. A weak ... allow you to monitor the ...
Medicine Products: